Full-Time

Supply Chain Quality Senior Specialist

Confirmed live in the last 24 hours

Viatris

Viatris

10,001+ employees

No salary listed

Senior

Dubai - United Arab Emirates

Category
Quality Control & Compliance
Operations & Logistics
Required Skills
SAP Products
Requirements
  • Hold Bachelor of Pharmacy/Pharmaceutical sciences degree is a Must.
  • Holding Quality related certificates is preferred.
  • Hold Pharmacist License from MOHAP - UAE.
  • Advanced computer skills, MS Office and enterprise systems such as SAP, TrackWise, Documentum platforms.
  • Demonstrated ability to prioritize work, to act and work independently and to report items as required to Team leader.
  • Self-Motivated; Operates with minimal supervision.
  • Demonstrated experience managing complex quality and compliance activities in a distribution center, Affiliate or with a contractor.
  • Demonstrated personal leadership to manage cross functional projects.
  • Demonstrated ability to resolve conflicts.
  • Takes initiatives and is proactive, persistent.
  • Command of English language required, must be also fluent in Arabic; multi-lingual is beneficial.
  • Strong verbal and written communication including presentation skills.
  • Shows strong negotiation skills.
  • Is diplomatic in communication with internal stake holders and external customers.
Responsibilities
  • Act as deputy Responsible Pharmacist for Viatris Middle East GSDP.
  • Support, as quality representative, new product launches, new Business Development projects and technology transfers.
  • Partner with colleagues to develop and negotiate quality agreements.
  • Drive the development, implementation and continuous improvement of Quality Systems to support regulatory requirements.
  • Proactively support regulatory inspections at CMO’s and ensure appropriate Viatris review/approval of responses to Regulatory Agencies including tracking of CAPA’s within Quality Tracking System (TrackWise).
  • Provide Quality Leadership for change management and significant deviations at distribution sites that may impact compliance status or require regulatory notifications.
  • Provide Quality Leadership and author support documentation for individual market release supporting documents to meet local regulatory requirements.
  • Ensure implementation of effective CAPA and quality system improvements based upon determined remediation activities.
  • Prepare Critical Quality Event (CQN) summaries and participate in relevant meetings.
  • Lead quality risk management activities and manage mitigation plans within CMO’s.
  • Accountable for the on-time disposition of commercial products in line with agreed schedule.
  • Provide Quality leadership for customer complaint investigations.
  • Provide support for regulatory activities involving TPQ managed Contract manufacturers.
  • Lead and/or provide support to quality projects and continuous improvement initiatives within TPQ and External Supply.
  • Primary focus of the role will be to support local Gulf, Levant & ITB Quality Operation identified which require liaison, information sharing, review and approval of documents and generation of deal specific documents, eg APQR's, complaint trend evaluations et.
  • Provide Quality support within the cross functional teams.
  • Participate in the establishment and maintenance of a Quality Management System and Quality Culture within Viatris Country in compliance with internal and Regulatory Authority expectations.
  • Participate in GDP/GMP internal audits and regulatory inspections within Viatris Country Office.
  • Track quality metrics, assess risks and implement actions to continuously improve performance.
Desired Qualifications
  • Holding Quality related certificates is preferred.
  • GMP experience is a plus.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • DOJ's clearance of Mylan improves Viatris' public image and reduces legal uncertainties.
  • Consistent dividend policy for five years reflects Viatris' financial stability.
  • Participation in major healthcare conferences boosts Viatris' investor engagement.

What critics are saying

  • Increased competition from biosimilars threatens Viatris' market share.
  • Expiration of key drug patents in 2025 may lead to revenue loss.
  • Reliance on international markets exposes Viatris to geopolitical risks.

What makes Viatris unique

  • Viatris bridges the gap between generics and branded drugs globally.
  • Exclusive licensing with Lexicon enhances Viatris' cardiovascular portfolio outside U.S. and Europe.
  • Viatris' commitment to innovation is evident in its cenerimod research for lupus treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 3rd, 2025
Viatris To Report Fourth Quarter And Full Year 2024 Financial Results On February 27, 2025

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc

PR Newswire
Oct 16th, 2024
Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases. Leverages Viatris' Unique Global Infrastructure and Expertise. Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe